

January 29, 2026

## Execution well on track...

**About the stock:** Bharat Electronics (BEL) is a leading aerospace and defence electronics company. It primarily manufactures advanced electronics products

- Multi-product, multi-technology - diverse product range including radar, missile systems, electronic warfare & avionics, anti-submarine warfare, electro-optics, homeland security, civilian products, etc
- Company's order backlog stands at ₹ 73015 crore as of Dec'25 end

### Investment Rationale:

- Healthy order-book position with robust pipeline:** BEL's order backlog stands at ₹ 73015 crore as of Dec-25 (2.8x TTM revenues), which provides healthy revenue growth visibility over the next 2-3 years considering the steady execution. Moreover, orders pipeline remains robust for BEL in defence electronic systems (including electronic warfare, radars, communication & control systems, navigation systems, avionics etc for various platforms), non-defence and exports. Management is confident in achieving their guidance of ~₹ 27000+ crore of order inflow in FY26E (~₹ 19500 crore worth of orders received in YTD FY26). Moreover, management expects large-scale QRSAM order (~₹ 30000 crore) to be placed in Q4FY26E (90% chances) or Q1FY27E with the company. Management's guidance of ~15+% YoY revenue growth with ~27% EBITDA margin has been reiterated, showing well-planned execution and increasing localisation of sub-systems and components
- Favourable ecosystem for domestic defence industry; Longer-term growth visibility remains healthy:** We believe that the defence electronics market in India is experiencing significant growth, driven by efforts to boost domestic production and reduce dependence on imports. As per the industry reports, defence electronics contribution increased to 30-35% in most platforms and is expected to increase further in the coming years, led by increasing required modernisation in platforms. With having strong capabilities in designing, developing & manufacturing a wide range of strategic electronic products/systems, we believe that BEL is strongly positioned to capture this huge opportunity considering MoD's push for greater indigenous content in large scale programs like aircrafts, warships, submarines, missiles, combat vehicles, unmanned ariel vehicles etc. Furthermore, non-defence areas (like space, railways, metros, civil aviation etc) and exports present sizable opportunity for BEL in the coming years. Management guides ~15% revenue CAGR over the next 3-4 years with gradual improvement in margins (led by increasing localisation and favourable product mix)

### Rating and Target Price

- With healthy order-backlog, robust pipeline and improving execution led by increasing indigenisation, we believe that BEL provides strong earnings visibility. We expect revenue & PAT CAGR at ~17% each over FY25-28E.
- We maintain BUY on BEL with a revised target price of ₹ 530 per share (based on 45x FY28E EPS)




### Particulars

| Particulars (Rs Crore) | Amount    |
|------------------------|-----------|
| Market Capitalization  | 3,25,285  |
| Total Debt (FY25)      | 0.0       |
| Cash and Inv (FY25)    | 9,545     |
| EV (FY25)              | 3,15,740  |
| 52 week H/L            | 436 / 240 |
| Equity capital         | 731.0     |
| Face value (Rs)        | 1.0       |

### Shareholding pattern

|          | Mar-25 | Jun-25 | Sep-25 | Dec-25 |
|----------|--------|--------|--------|--------|
| Promoter | 51.1   | 51.1   | 51.1   | 51.1   |
| FII      | 17.6   | 18.6   | 18.1   | 18.5   |
| DII      | 20.9   | 20.6   | 20.9   | 20.5   |
| Others   | 10.4   | 9.7    | 9.8    | 9.9    |

### Price Chart



### Key risks

- (i) Dependent on govt contracts
- (ii) High working capital requirement
- (iii) Availability of key raw materials/components

### Research Analyst

Vijay Goel  
vijay.goel@icicisecurities.com

Kush Bhandari  
kush.bhandari@icicisecurities.com

### Key Financial Summary

| (Year-End March)  | FY22   | FY23   | FY24   | FY25   | 3 Year CAGR (FY22-25) | FY26E  | FY27E  | FY28E  | 3 Year CAGR (FY25-28E) |
|-------------------|--------|--------|--------|--------|-----------------------|--------|--------|--------|------------------------|
| Revenues          | 15,368 | 17,734 | 20,268 | 23,769 | 15.6                  | 27,453 | 32,175 | 37,966 | 16.9                   |
| EBITDA            | 3,341  | 4,086  | 5,046  | 6,834  | 26.9                  | 7,467  | 9,009  | 10,744 | 16.3                   |
| EBITDA margin (%) | 21.7   | 23.0   | 24.9   | 28.8   |                       | 27.2   | 28.0   | 28.3   |                        |
| Net Profit        | 2,400  | 2,986  | 3,985  | 5,323  | 30.4                  | 5,873  | 7,137  | 8,583  | 17.3                   |
| EPS (Rs)          | 3.3    | 4.1    | 5.5    | 7.3    |                       | 8.0    | 9.8    | 11.7   |                        |
| P/E (x)           | 135.5  | 108.9  | 81.6   | 61.1   |                       | 55.4   | 45.6   | 37.9   |                        |
| EV/EBITDA (x)     | 95.1   | 77.6   | 62.3   | 46.2   |                       | 42.0   | 34.3   | 28.4   |                        |
| RoCE (%)          | 25.8   | 28.4   | 32.3   | 35.6   |                       | 33.0   | 33.4   | 33.5   |                        |
| RoE (%)           | 19.5   | 21.5   | 24.4   | 26.6   |                       | 24.8   | 25.1   | 25.1   |                        |

Source: Company, ICICI Direct Research

### Q3 and 9MFY26 Result Summary

- Operational performance during the quarter improved significantly on YoY basis led by strong execution
- Revenue increased by 24% YoY (+23.5% QoQ) to ₹ 7154 crore
- EBITDA margin improved by 81 bps on YoY basis (+35 bps on QoQ) to 29.7%, led by better execution and increasing indigenisation
- EBITDA grew by 27.4 % YoY (+25 % QoQ) to ₹ 2127 crore. PAT was up 20.4% YoY (+22.7 % QoQ) to ₹ 1580 crore
- For 9MFY26, revenue stood at ₹17,386 crore (+18.9% YoY) with EBITDA margin improving to 29.1% (+167 bps YoY) as execution remained healthy. PAT for the period increased by 20.0% YoY to ₹3,836 crore.

### Q3FY26 highlights

- Management has reiterated its guidance for revenue growth at ~15+% YoY with an EBITDA margin at ~27+% for FY26E
- Order inflow guidance for the year also remained at ~₹ 27000 crore. This is excluding QRSAM contract worth Rs 30000 crore. However, management expects 90% chances of receiving this contract by Mar-26
- Order backlog stands at ₹ 73015 crore as of Dec-25 end which has an equal spread of orders from the tri-services. Order inflows during the 9MFY26 stands at ₹ 19300 crore
- The order book now comprises of major orders consisting of Long-Range Surface to Air Missile (LRSAM), Electric Fuses, Akash Prime, BMP 2 upgrade, together contributing ~₹ 20,000 crore to the order book
- Defence contributes ~90% of the revenue while non-defence segment contributes ~10%
- During the quarter major orders executed include LRSAM project, Himshakti project, Battlefield Surveillance Project, Lynx Fire Control Solution, Akash Prime, LRUs for LCA Mk1A, and Shakti EW system.
- The management is planning to complete 90% of Akash Prime this year while post clearance of Akash NG and order of ₹ 2500-3000 crore is expected earliest by Q4FY27E
- Major orders that the company expects to execute in Q4FY26E consists of LRFM, Himshakti project, Akash Prime, D-29 AW system, LRUs for LCA Mk1A, Arudra MPR, BMP-2 etc
- The management expects orders to the tune of ₹ 25,000+ crore in FY27E
- During Q4FY26E, the management expects any one of Shatrughat and Samaghat projects (remaining by H1FY27E), Next-Generation Corvette (NGC) orders of about ₹ 2500-3000 crore (remaining by H1FY27E), LCA-Tejas avionics for follow-on 97 jets, Chatrah project
- RFP for QRSAM has now been submitted. This order would have an execution timeline of 5-6 years as it has various stages
- On the Advance-Medium Combat Aircraft (AMCA) front the company has entered in a 50:50 partnership with L&T
- With regard to Project Kusha (indigenous S-400), the company expects orders similar to QRSAM by FY28-29
- Company targets non-defence revenue contribution to increase to 10% in medium term and 15% in long term
- In terms of exports, management targets to increase its share to 5% in near term and 10% in long-term
- Concerning capital expenditures, the management is focused on developing new facilities in different locations, some of which may be

larger than the existing ones. To facilitate this, an annual investment of ₹ 1000 crore is expected.

- The company invests 6-7% of its revenue towards R&D and has planned a ~₹ 1700 crore investment in FY26E for the same and aims to increase these expenses by 20% every year going forward
- In regarding to Free-Trade Agreement, the management is positive about a possibility of setting up a research laboratory in collaboration with EU nations

#### Exhibit 1: Q2 and H2FY26 result snapshot (₹ crore)

|                     | Q3FY26  | Q3FY25  | YoY (%) | Q2FY26  | QoQ (%) | Comments  | 9MFY26   | 9MFY25   | YoY(%)  |
|---------------------|---------|---------|---------|---------|---------|---|----------|----------|---------|
| Net Sales           | 7,153.9 | 5,770.7 | 24.0    | 5,792.1 | 23.5    | Revenue growth steady led by strong execution                         | 17,385.7 | 14,619.2 | 18.9    |
| Other income        | 138.5   | 186.4   |         | 153.9   |         |   | 455.8    | 547.7    |         |
| Total Revenue       | 7,292.4 | 5,957.1 |         | 5,946.0 |         |   | 17,841.5 | 15,166.9 |         |
| Raw materials costs | 3,824.5 | 2,981.4 |         | 2,838.6 |         |   | 8,739.1  | 7,438.3  |         |
| Employees Expenses  | 819.9   | 672.0   |         | 767.8   |         |   | 2,284.1  | 1,994.6  |         |
| Other Expenses      | 382.2   | 447.9   |         | 483.6   |         |   | 1,294.7  | 1,168.7  |         |
| Total Expenditure   | 5,026.6 | 4,101.2 |         | 4,089.9 |         |   | 12,318.0 | 10,601.5 |         |
| EBITDA              | 2,127.2 | 1,669.5 | 27.4    | 1,702.2 | 25.0    |   | 5,067.7  | 4,017.6  | 26.1    |
| EBITDA margins (%)  | 29.7    | 28.9    | 81 bps  | 29.4    | 35 bps  | Margin improved led by better execution and increasing indigenisation | 29.1     | 27.5     | 167 bps |
| Interest            | 2.0     | 1.3     |         | 1.7     |         |   | 5.1      | 3.8      |         |
| Depreciation        | 135.4   | 110.9   |         | 126.5   |         |   | 382.7    | 329.8    |         |
| Tax                 | 558.1   | 442.4   |         | 449.5   |         |   | 1,326.3  | 1,065.6  |         |
| PAT                 | 1,579.7 | 1,311.6 | 20.4    | 1,287.2 | 22.7    |   | 3,835.9  | 3,195.7  | 20.0    |

Source: Company, ICICI Direct Research

## Financial Summary

**Exhibit 2: Profit and loss statement**

₹ crore

| Year-End March               | FY25   | FY26E  | FY27E   | FY28E   |
|------------------------------|--------|--------|---------|---------|
| Revenue                      | 23,769 | 27,453 | 32,175  | 37,966  |
| % Growth                     | 17.3   | 15.5   | 17.2    | 18.0    |
| Other income                 | 742.4  | 890.8  | 1,113.5 | 1,391.9 |
| Total Revenue                | 23,769 | 27,453 | 32,175  | 37,966  |
| % Growth                     | 17.3   | 15.5   | 17.2    | 18.0    |
| Total Raw Material Costs     | 12,187 | 14,358 | 16,731  | 19,629  |
| Employee Expenses            | 2,761  | 3,294  | 3,861   | 4,556   |
| other expenses               | 1,987  | 2,333  | 2,574   | 3,037   |
| Total Operating Expenditure  | 16,935 | 19,986 | 23,166  | 27,222  |
| Operating Profit (EBITDA)    | 6,834  | 7,467  | 9,009   | 10,744  |
| % Growth                     | 35.4   | 9.3    | 20.6    | 19.3    |
| Interest                     | 10     | 8      | 9       | 9       |
| PBDT                         | 7,566  | 8,350  | 10,114  | 12,128  |
| Depreciation                 | 467    | 527    | 602     | 676     |
| PBT before Exceptional Items | 7,099  | 7,823  | 9,512   | 11,452  |
| Total Tax                    | 1,812  | 1,995  | 2,426   | 2,920   |
| PAT before MI                | 5,287  | 5,828  | 7,087   | 8,532   |
| PAT                          | 5,323  | 5,873  | 7,137   | 8,583   |
| % Growth                     | 33.6   | 10.3   | 21.5    | 20.3    |
| EPS                          | 7.3    | 8.0    | 9.8     | 11.7    |

Source: Company, ICICI Direct Research

**Exhibit 3: Cash Flow Statement**

| Year-End March                   | FY25    | FY26E   | FY27E   | FY28E   |
|----------------------------------|---------|---------|---------|---------|
| Profit after Tax                 | 5,323   | 5,873   | 7,137   | 8,583   |
| Depreciation                     | 467     | 527     | 602     | 676     |
| Interest                         | 10      | 8       | 9       | 9       |
| Cash Flow before WC changes      | 5,800   | 6,408   | 7,747   | 9,267   |
| Changes in inventory             | (1,672) | (1,411) | (1,370) | (2,246) |
| Changes in debtors               | (1,724) | (1,414) | (1,370) | (2,142) |
| Changes in loans & Advances      | (0)     | (0)     | (0)     | (0)     |
| Changes in other current assets  | 941     | (931)   | (1,275) | (1,564) |
| Net Increase in Current Assets   | (2,306) | (3,756) | (4,016) | (5,952) |
| Changes in creditors             | (368)   | 798     | 1,152   | 952     |
| Changes in provisions            | 45      | 88      | 230     | 190     |
| Net Inc in Current Liabilities   | (2,274) | 3,619   | 4,310   | 4,733   |
| Net CF from Operating activities | 1,219   | 6,272   | 8,041   | 8,048   |
| Changes in deferred tax assets   | 40      | -       | -       | -       |
| (Purchase)/Sale of Fixed Assets  | (904)   | (1,000) | (1,000) | (1,000) |
| Net CF from Investing activities | (940)   | (1,790) | (1,275) | (1,337) |
| Dividend and Dividend Tax        | (1,754) | (1,937) | (2,339) | (2,778) |
| Net CF from Financing Activities | (1,790) | (2,217) | (2,383) | (2,865) |
| Net Cash flow                    | (1,512) | 2,264   | 4,384   | 3,846   |
| Opening Cash/Cash Equivalent     | 11,057  | 9,545   | 11,809  | 16,193  |
| Closing Cash/ Cash Equivalent    | 9,545   | 11,809  | 16,193  | 20,039  |

Source: Company, ICICI Direct Research

**Exhibit 4: Balance Sheet**

₹ crore

| Year-End March                | FY25   | FY26E  | FY27E  | FY28E  |
|-------------------------------|--------|--------|--------|--------|
| Equity Capital                | 731.0  | 731.0  | 731.0  | 731.0  |
| Reserve and Surplus           | 19,243 | 22,983 | 27,745 | 33,472 |
| Total Shareholders funds      | 19,974 | 23,714 | 28,476 | 34,203 |
| Other Non Current Liabilities | 73.3   | 73.3   | 73.3   | 73.3   |
| Total Debt                    | -      | -      | -      | -      |
| Total Liabilities             | 21,079 | 24,819 | 29,582 | 35,308 |
| Gross Block                   | 6,584  | 7,637  | 8,637  | 9,636  |
| Acc: Depreciation             | 3,379  | 3,907  | 4,508  | 5,184  |
| Net Block                     | 3,205  | 3,731  | 4,129  | 4,452  |
| Capital WIP                   | 477    | 500    | 500    | 501    |
| Total Fixed Assets            | 4,471  | 5,020  | 5,419  | 5,743  |
| Non Current Assets            | 1,342  | 2,132  | 2,407  | 2,744  |
| Inventory                     | 9,119  | 10,530 | 11,900 | 14,146 |
| Debtors                       | 9,116  | 10,530 | 11,900 | 14,042 |
| Loans and Advances            | 1      | 2      | 2      | 2      |
| Other Current Assets          | 6,481  | 7,412  | 8,687  | 10,251 |
| Cash                          | 9,545  | 11,809 | 16,193 | 20,039 |
| Total Current Assets          | 34,858 | 40,878 | 49,277 | 59,076 |
| Current Liabilities           | 3,339  | 4,137  | 5,289  | 6,241  |
| Provisions                    | 902    | 902    | 902    | 902    |
| Total Current Liabilities     | 19,753 | 23,372 | 27,682 | 32,415 |
| Net Current Assets            | 15,105 | 17,506 | 21,595 | 26,660 |
| Total Assets                  | 21,079 | 24,819 | 29,582 | 35,308 |

Source: Company, ICICI Direct Research

**Exhibit 5: Key ratios**

| (Year-end March)         | FY25 | FY26E | FY27E | FY28E |
|--------------------------|------|-------|-------|-------|
| EPS                      | 7.3  | 8.0   | 9.8   | 11.7  |
| Cash per Share           | 13.1 | 16.2  | 22.2  | 27.4  |
| BV                       | 27.3 | 32.4  | 39.0  | 46.8  |
| Dividend per share       | 2.4  | 2.7   | 3.2   | 3.8   |
| Dividend payout ratio    | 33%  | 33%   | 33%   | 32%   |
| EBITDA Margin            | 28.8 | 27.2  | 28.0  | 28.3  |
| PAT Margin               | 22.4 | 21.4  | 22.2  | 22.6  |
| RoE                      | 26.6 | 24.8  | 25.1  | 25.1  |
| RoCE                     | 35.6 | 33.0  | 33.4  | 33.5  |
| RoIC                     | 61.0 | 58.3  | 68.4  | 71.1  |
| EV / EBITDA              | 46.2 | 42.0  | 34.3  | 28.4  |
| P/E                      | 61.1 | 55.4  | 45.6  | 37.9  |
| EV / Net Sales           | 13.3 | 11.4  | 9.6   | 8.0   |
| Sales / Equity           | 1.2  | 1.2   | 1.1   | 1.1   |
| Market Cap / Sales       | 13.7 | 11.8  | 10.1  | 8.6   |
| Price to Book Value      | 16.3 | 13.7  | 11.4  | 9.5   |
| Asset turnover           | 1.2  | 1.2   | 1.1   | 1.1   |
| Debtors Turnover Ratio   | 2.9  | 2.8   | 2.9   | 2.9   |
| Creditors Turnover Ratio | 6.7  | 7.3   | 6.8   | 6.6   |
| Debt / Equity            | -    | -     | -     | -     |
| Current Ratio            | 4.5  | 4.5   | 4.2   | 4.3   |
| Quick Ratio              | 2.9  | 2.8   | 2.7   | 2.7   |

Source: Company, ICICI Direct Research

## RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,  
ICICI Securities Limited,  
Third Floor, Brillanto House,  
Road No 13, MIDC,  
Andheri (East)  
Mumbai – 400 093  
research@icicidirect.com

## ANALYST CERTIFICATION

I/We, Vijay Goel, PGDBM, Kush Bhandari, MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock broking and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on [www.icicibank.com](http://www.icicibank.com).

**Investments in securities market are subject to market risks. Read all the related documents carefully before investing.**

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: [complianceofficer@icicisecurities.com](mailto:complianceofficer@icicisecurities.com)

For any queries or grievances: Mr. Jeetu Jawrani Email address: [headservicequality@icicidirect.com](mailto:headservicequality@icicidirect.com) Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit [icicidirect.com](http://icicidirect.com) to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report